{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antitubercular+Agents", "query": { "condition": "Antitubercular Agents" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antitubercular+Agents&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T05:43:45.624Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00000959", "title": "Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Tuberculosis" ], "interventions": [ { "name": "Isoniazid", "type": "DRUG" }, { "name": "Pyridoxine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 600, "start_date": null, "completion_date": "1996-06", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-05-22T05:43:45.624Z", "location_count": 14, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000959" }, { "nct_id": "NCT00685360", "title": "A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tuberculosis, Pulmonary", "Tuberculosis, Multidrug Resistant", "Extensively Drug-Resistant Tuberculosis" ], "interventions": [ { "name": "Delamanid", "type": "DRUG" }, { "name": "Optimized Background Regimen (OBR)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 481, "start_date": "2008-05-08", "completion_date": "2010-06-11", "has_results": true, "last_update_posted_date": "2021-12-01", "last_synced_at": "2026-05-22T05:43:45.624Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00685360" }, { "nct_id": "NCT01162486", "title": "Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tuberculosis", "Tuberculosis, Pulmonary" ], "interventions": [ { "name": "Rifampin & midazolam", "type": "DRUG" }, { "name": "rifapentine and midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2010-04", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2019-05-07", "last_synced_at": "2026-05-22T05:43:45.624Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01162486" }, { "nct_id": "NCT00000947", "title": "A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mycobacterium Avium-intracellulare Infection", "HIV Infections" ], "interventions": [ { "name": "Azithromycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 850, "start_date": null, "completion_date": "2000-07", "has_results": false, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-05-22T05:43:45.624Z", "location_count": 19, "location_summary": "San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000947" }, { "nct_id": "NCT00000950", "title": "Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Tuberculosis" ], "interventions": [ { "name": "Ethambutol hydrochloride", "type": "DRUG" }, { "name": "Isoniazid", "type": "DRUG" }, { "name": "Pyrazinamide", "type": "DRUG" }, { "name": "Pyridoxine hydrochloride", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 50, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-02", "last_synced_at": "2026-05-22T05:43:45.624Z", "location_count": 13, "location_summary": "Los Angeles, California • Torrance, California • Miami, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000950" }, { "nct_id": "NCT00000636", "title": "Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Tuberculosis" ], "interventions": [ { "name": "Isoniazid", "type": "DRUG" }, { "name": "Pyrazinamide", "type": "DRUG" }, { "name": "Pyridoxine hydrochloride", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 2000, "start_date": null, "completion_date": "1997-10", "has_results": false, "last_update_posted_date": "2021-11-02", "last_synced_at": "2026-05-22T05:43:45.624Z", "location_count": 25, "location_summary": "San Francisco, California • Denver, Colorado • New Haven, Connecticut + 15 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000636" }, { "nct_id": "NCT00000638", "title": "Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Tuberculosis" ], "interventions": [ { "name": "Isoniazid", "type": "DRUG" }, { "name": "Pyrazinamide", "type": "DRUG" }, { "name": "Pyridoxine hydrochloride", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 2000, "start_date": null, "completion_date": "1999-09", "has_results": false, "last_update_posted_date": "2021-11-02", "last_synced_at": "2026-05-22T05:43:45.624Z", "location_count": 75, "location_summary": "Birmingham, Alabama • Los Angeles, California • Oakland, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000638" }, { "nct_id": "NCT00002032", "title": "Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mycobacterium Avium-intracellulare Infection", "HIV Infections" ], "interventions": [ { "name": "Rifabutin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacia", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-05-22T05:43:45.624Z", "location_count": 33, "location_summary": "Irvine, California • Sylmar, California • Denver, Colorado + 22 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002032" }, { "nct_id": "NCT01381757", "title": "Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Tuberculosis, Pulmonary", "Mycobacterium Tuberculous", "Antitubercular Agents", "Tuberculosis, Mulutidrug-Resistant", "Extensively Drug-Resistant", "Extensibely Drug-Resistant Tuberculosis" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 34, "start_date": "2011-05-31", "completion_date": "2013-03-05", "has_results": false, "last_update_posted_date": "2018-04-05", "last_synced_at": "2026-05-22T05:43:45.624Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01381757" }, { "nct_id": "NCT00964041", "title": "Once Weekly D-cycloserine for Schizophrenia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "D-cycloserine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2009-07", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2013-11-20", "last_synced_at": "2026-05-22T05:43:45.624Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00964041" } ] }